Sites Menu > *APSFA's Favorites


*APSFA's Favorites


Antiphospho....what?!

The APS Foundation of America, Inc. is the only United States nonprofit health agency dedicated to bringing national awareness to Antiphospholipid Antibody Syndrome (APS), the major cause of multiple miscarriages, thrombosis, young strokes and heart attacks. We are a volunteer run, community based 501(c)3 non-profit Public Charity organization and is dedicated to fostering and facilitating joint efforts in the areas of education, support, public awareness, research and patient services.

**APS Friends & Support Forum

A forum run by Heidi & Tina founders of the APS Foundation of America, Inc., a non profit organization. This forum is an information source and a friendly support group for people who have Antiphospholipid Antibody Syndrome or for anyone who's lives are touched by it. It is sometimes referred to as APS, APLS, or APLA and is known as Hughes Syndrome or "Sticky Blood" in the UK. APS is associated with recurrent clotting events including premature stroke, repeated miscarriages, phlebitis, venous thrombosis and pulmonary thromboembolism. If this disease touches your life in some way, please feel free to join in our discussions! :) We're glad to have you visit!

Thrombosis Interest Group of Canada

The Thrombosis Interest Group of Canada consists of a group of 40 specialists in fields related to thrombosis who collaborate to write evidence-based or consensus-based clinical guides on the investigation, management, and diagnosis of thrombotic disorders.

Rare Diseases Clinical Research Network

The Rare Diseases Clinical Research Network was created to facilitate collaboration among experts in many different types of rare diseases. Our goal is to contribute to the research and treatment of rare diseases by working together to identify biomarkers for disease risk, disease severity and activity, and clinical outcome, while also encouraging development of new approaches to diagnosis, prevention, and treatment.

FDA Vitamin K List


Antiphospholipid Antibody Syndrome

A forum run by the APS Foundation of America, Inc., a non profit organization. This forum is an information source and a friendly support group for people who have Antiphospholipid Antibody Syndrome or for anyone who's lives are touched by it. It is sometimes referred to as APS, APLS, or APLA and is known as Hughes Syndrome or "Sticky Blood" in the UK. APS is associated with recurrent clotting events including premature stroke, repeated miscarriages, phlebitis, venous thrombosis and pulmonary thromboembolism. If this disease touches your life in some way, please feel free to join in our discussions! :) We're glad to have you visit!

Antiphospholipid Antibody Syndrome (APS)

Neuroland

2009 H1N1 Flu (referred to as "swine flu" early on) and Seasonal Flu Information for People with Inflammatory Arthritis or Rheumatic Disease


The Antiphospholipid Story

© 2003. The Journal of Rheumatology Publishing Company Limited.

Surgical Management of the Primary Dental Patient on Warfarin

Written to inform Dentists about treating Warfarin Patients

eMedicine - Antiphospholipid Antibody Syndrome : Article by Barry L Myones, MD

Last Updated: October 26, 2004 Promtes an INR in the range of 2.5-3.5.

**GoodSearch.com

What if APS Foundation of America - APSFA earned a penny every time you searched the Internet? Well, now we can! GoodSearch.com is a new search engine that donates half its revenue, about a penny per search, to the charities its users designate. You use it just as you would any search engine, and it's powered by Yahoo!, so you get great results. Just go to http://www.goodsearch.com and be sure to enter APS Foundation of America - APSFA as the charity you want to support. Just 500 of us searching four times a day will raise about $7300 in a year without anyone spending a dime! And, be sure to spread the word!

Antiphospholipid Syndrome from eMedicine

Last Updated: December 5, 2004 Author: Steven Carsons, MD, Chief, Division of Rheumatology, Allergy, and Immunology, Professor of Medicine, Department of Internal Medicine, Winthrop University Hospital, State University of New York at Stony Brook

Antiphospholipid Antibodies

Circulation. 2005;112:e39-e44. © 2005 American Heart Association, Inc. Caron P. Misita, PharmD; Stephan Moll, MD

*Medic Alert

HIGHLY recommended! This jewerly could save your life!

eMedicine - Antiphospholipid Syndrome : Article by Steven Carsons, MD

Last Updated: December 5, 2004 Based on the most recent evidence, a reasonable target for the international normalized ratio (INR) is 2.6-3 for a minimum of 6 months for a first thrombosis. Patients with recurrent thrombotic events while well maintained on the above regimen may require an INR of 3-4 and generally receive anticoagulation therapy for life. For severe or refractory cases, a combination of warfarin and aspirin may be used.

Rare Thrombotic Diseases Consortium (RTDC)

The Rare Thrombotic Diseases Consortium (RTDC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of and improving the care of patients with thrombotic diseases. Funded by the National Institutes of Health (NIH), the RTDC is part of the Rare Diseases Clinical Research Network. The operations of the RTDC are directed from Duke University. Other primary RTDC study sites include the University of North Carolina, University of Wisconsin, Centers for Disease Control and Prevention, and the Mayo Clinic.

Medical Progress- Antiphospholipid Antibody Syndrome

PDF File from the New England Journal of Medicine

Listen to the Patient: Anticoagulation Is Critical in the Antiphospholipid (Hughes) Syndrome

2003. The Journal of Rheumatology Publishing Company Limited. Promotes an INR of greater than 3.0.

Warfarin in Antiphospholipid Syndrome: Time to Explore New Horizons

The Journal of Rheumatology Feb. 2005

Monitoring Warfarin Therapy in Patients with Lupus Anticoagulants

Recommended therapeutic international normalized ratios (INRs) for oral anticoagulation in patients with lupus anticoagulants who sustain a thromboembolic event are controversial. Patients with lupus anticoagulants often have a prolonged prothrombin time, which may complicate management of anticoagulant therapy.

*National Blood Clot Alliance

The mission of the National Blood Clot Alliance is to prevent, diagnose and treat thrombosis and thrombophilia through research, education, support and advocacy.

Antiphospholipid Syndrome

by Erik Letko, M.D. Promotes an INR of greater that 3.0.

Warfarin in Antiphospholipid Syndrome: Time to Explore New Horizons

The Journal of Rheumatology Feb. 2005 Promotes an INR of greater than 3.0.

Duration of Oral Anticoagulant Therapy for Venous Thromboembolism



[1] [2] [3] Next



 

 

The APS Foundation of America, Inc. website and forums are both volunteer run and funded by donations to the APSFA.

Website hosted by Dreamhost. Website created and maintained by Heidi P.

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

APS Foundation of America, Inc. will be building a database with your email, name and address information for future mailings. Your information will be kept confidential and not sold to any third parties. You may opt out at anytime by emailing us.

APSFA ©2005-2016 | APSFA Privacy Policy | APSFA Advertising Policy | 501(c)3 Public Charity EIN #203085295